VIDEO: Studies focusing on understanding tumor biology could advance sarcoma field
Click Here to Manage Email Alerts
In this video, Candace Haddox, MD, discussed a few presentations from the Connective Tissue Oncology Society Annual Meeting that focused on how better understanding of sarcoma biology could lead to clinical advancement.
“We are seeing progress in understanding sarcoma biology and, importantly, we’re incorporating this knowledge into rational clinical trial and drug development that targets the tumor’s unique biology,” Haddox, a sarcoma medical oncologist at Dana-Farber Cancer Institute, told Healio. “There were a few great examples of this at the meeting.”
Haddox highlighted a study presented at the meeting on the efficacy and safety of the MDM2 inhibitor brigimadlin (BI 907828) in patients with liposarcoma.
Another “especially compelling” phase 1 study showed that as a proof of principle, a bromodomain-containing protein 9 degrader “could work for synovial sarcoma,” according to Haddox.
Haddox also discussed the “notable activity” seen with a CDK9 inhibitor, known as KB-0742, in sarcomas with transcription factor fusions.
Finally, she talked about rogaratinib’s “promising activity” in succinate dehydrogenase-deficient gastrointestinal stromal tumor (GIST).
References:
- Livingston A, et al. Paper 25. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Merriam P, et al. Paper 84. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Schöffski P, et al. Paper 23. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
- Van Tine BA, et al. Paper 26. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Collapse
Click Here to Manage Email Alerts